Ferumoxytol Approved to Treat Iron Deficiency Anemia in CKD Patients
AMAG Pharmaceuticals, of Lexington, Mass., has received marketing clearance for Feraheme (ferumoxytol) Injection as a treatment for iron deficiency anemia in adult CKD patients.
AMAG Pharmaceuticals, of Lexington, Mass., has received marketing clearance for Feraheme (ferumoxytol) Injection as a treatment for iron deficiency anemia in adult CKD patients.
Regular low-dose infusions may offer advantages over loading doses in anemic hemodialysis patients.
Although the healthful effects of vitamin C are well-established, there are concerns about excessive intake of this vitamin by CKD patients.
AMAG Pharmaceuticals, Inc., of Lexington, Mass., has received a Complete Response letter from the FDA regarding ferumoxytol for the treatment of iron deficiency anemia (IDA) in CKD patients.
Data from a German study suggest that IV-administered epoetin zeta—a new erythropoietin preparation—is safe for maintenance treatment of anemia in patients with end-stage renal disease.
Ferumoxytol, a novel, semi-synthetic, superparamagnetic iron oxide nanoparticle administered by injection, is well tolerated and has a safety profile similar to placebo in CKD patients with anemia, according to a report in the American Journal of Kidney Diseases.
Iron from dietary sources is inadequate to address functional iron deficiency associated with ESA use.
Elevated C-reactive protein (CRP) levels, a marker of inflammation, predict greater requirements of erythropoiesis-stimulating agents (ESAs).
Patients on hemodialysis and CKD patients not dialysis have a better hemoglobin response when treated with IV iron than with oral iron, but the difference in effect is stronger in hemodialysis patients, a meta-analysis showed.
Black patients on long-term hemodialysis receive greater doses of erythropoietin (EPO) than their white counterparts even though both races achieve similar hemoglobin levels, data show.